Samalin Investment Counsel’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Samalin Investment Counsel’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-21,015	Closed	-$15K	–	249
2020 Q4	$15K	Hold	21,015	–	–	0.01%	223
2020 Q3	$47K	Buy	21,015 +330	+2%	+$942	0.04%	197
2020 Q2	$74K	Buy	+20,685	New	+$74.6K	0.08%	165
2020 Q1	–	Sell	-996	Closed	-$3K	–	556
2019 Q4	$3K	Buy	+996	New	+$2.59K	﹤0.01%	504

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Samalin Investment Counsel's BMY.RT Position: Q1 2021 in Review

Samalin Investment Counsel sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 21,015 shares — an estimated $15K sold.

Samalin Investment Counsel first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $74K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Samalin Investment Counsel reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Samalin Investment Counsel sold 21,015 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $15K.
Samalin Investment Counsel first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Samalin Investment Counsel's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $74K in Q2 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Samalin Investment Counsel's 13F filing for Q1 2021, filed 11 May 2021.